Pterostilbene is an effective chemopreventive agent against multiple types of
cancer cells. A novel
pterostilbene derivative,
ANK-199, was designed and synthesized by our group. Its antitumor activity and mechanism in
cisplatin-resistant CAR human
oral cancer cells were investigated in this study. Our results show that
ANK-199 has an extremely low toxicity in normal oral cell lines. The formation of autophagic vacuoles and acidic vesicular organelles (AVOs) was observed in the ANK-199-treated CAR cells by
monodansylcadaverine (MDC) and
acridine orange (AO) staining, suggesting that
ANK-199 is able to induce autophagic cell death in CAR cells. Neither DNA fragmentation nor
DNA condensation was observed, which means that ANK-199-induced cell death is not triggered by apoptosis. In accordance with morphological observation, 3-MA, a specific inhibitor of PI3K
kinase class III, can inhibit the autophagic vesicle formation induced by
ANK-199. In addition,
ANK-199 is also able to enhance the
protein levels of autophagic
proteins, Atg complex,
beclin 1, PI3K class III and LC3-II, and
mRNA expression of autophagic genes Atg7, Atg12,
beclin 1 and LC3-II in the ANK-199-treated CAR cells. A molecular signaling pathway induced by
ANK-199 was therefore summarized. Results presented in this study show that
ANK-199 may become a novel therapeutic
reagent for the treatment of
oral cancer in the near future (patent pending).